CJC 1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). It is a modified form of GHRH (1-29) with improved pharmacokinetics, especially in regard to half-life.
CJC 1295 has been investigated in a variety of animal and human studies. The results of these studies have shown that CJC 1295 is a potent stimulator of growth hormone release.
Animal studies
CJC 1295 has been shown to increase growth hormone levels in a variety of animal species, including rats, mice, rabbits, and dogs. In one study, rats that were given CJC 1295 had significantly higher growth hormone levels than rats that were given a placebo.
Human studies
CJC 1295 has also been shown to increase growth hormone levels in humans. In one study, healthy adult males who were given CJC 1295 had significantly higher growth hormone levels than males who were given a placebo.
In another study, patients with growth hormone deficiency (GHD) who were given CJC 1295 had a significant increase in their growth hormone levels. CJC 1295 has also been shown to improve growth and development in children with GHD.
Other potential benefits of CJC 1295
In addition to its effects on growth hormone levels, CJC 1295 is also being investigated for its potential benefits in a variety of other conditions, including:
- Aging: CJC 1295 is being investigated for its potential to slow down the aging process and improve cognitive function in the elderly.
- Alzheimer’s disease: CJC 1295 is being investigated for its potential to treat Alzheimer’s disease, a neurodegenerative disease that causes dementia.
- Parkinson’s disease: CJC 1295 is being investigated for its potential to treat Parkinson’s disease, a neurodegenerative disease that causes tremors and other movement disorders.
- Multiple sclerosis (MS): CJC 1295 is being investigated for its potential to treat MS, an autoimmune disease that damages the myelin sheath that insulates nerve fibers.
- Spinal cord injury (SCI): CJC 1295 is being investigated for its potential to promote nerve regeneration and improve neurological function after SCI.
- Traumatic brain injury (TBI): CJC 1295 is being investigated for its potential to improve neurological function and cognitive function after TBI.
- Sarcopenia: CJC 1295 is being investigated for its potential to treat sarcopenia, a loss of muscle mass and strength that occurs with age.
- Cachexia: CJC 1295 is being investigated for its potential to treat cachexia, a loss of muscle mass and strength that occurs in chronic diseases such as cancer and HIV/AIDS.
CJC 1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). It is a modified form of GHRH (1-29) with improved pharmacokinetics, especially in regard to half-life.
CJC 1295 has been shown to increase growth hormone levels in animals and humans. It is also being investigated for its potential benefits in a variety of other conditions, including aging, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, spinal cord injury, traumatic brain injury, sarcopenia, and cachexia.
However, it is important to note that CJC 1295 is not yet approved by the FDA for any use. More research is needed to determine its safety and efficacy in humans.
